Get started
Author

Aubrey Lasko

Observed names: Aubrey R Lasko, Aubrey R. Johnson, Lasko, Aubrey
ORCID: 0009-0007-0684-2654
Observed ORCID: 0009-0007-0684-2654
OpenAlex ID: A5091964396
Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey
2023 · Shawn P Griffin, Jessie R Signorelli, et al. · Journal of Oncology Pharmacy Practice · 11
PDF
Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events
2022 · Samantha Brongiel, Kristen L. Rychalsky, et al. · Annals of Pharmacotherapy · 6
A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib
2026 · Thomas J. Roberts, Catherine B. Meador, et al. · Thyroid · 2
Time to complete oncology pharmacist tasks: A joint opinion of the Hematology/Oncology Pharmacy Association and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network
2025 · Shawn P Griffin, Jessie Signorelli, et al. · Journal of Oncology Pharmacy Practice · 2
Durvalumab Combined With Pemetrexed-Based Chemotherapy in Trial-Ineligible Patients With Mesothelioma: A Brief Report
2024 · Ibiayi Dagogo-Jack, Aubrey Lasko, et al. · JTO Clinical and Research Reports · 1
PDF
Works count: 7
Citation count: 22
H-index: 2
I10-index: 1
Year
Topic
Type